Synonyms: PF-05082566
Compound class:
Antibody
Comment: Utomilumab is a fully human IgG2 monoclonal antibody with agonist activity at the tumour necrosis factor (TNF) receptor, 4-1BB (TNFRSF9), being investigated for potential clinical anti-tumour activity [1].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. ![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
Immunopharmacology Comments |
Utomilumab acts as a 4-1BB (CD137) agonist, and effects immunotherapeutic modulation of T cells to improve cancer immuneosurveillance and antitumour immunity [1]. 4-1BB agonists may work by releasing the transcription factor eomesodermin from ThPOK repression in CD4 T cells [2]. |